Skip to content
Biodatica
Start free

Investigator

Michael David Alpert

EMMUNE, INC · funded by NIAID

Companies
3

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$2.3M

Summed across those awards.

First award
Jan 1, 2023

Latest May 9, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

  • EMMUNE, INC

    ImmunologyGrant-only

    Momentum in another area
  • EMMUNE, INC

    ImmunologyGrant-only

    Momentum in another area
  • EMMUNE, INC

    ImmunologyGrant-only

    Momentum in another area

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R43

    IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic

    $300k

    May 9, 2025NIAIDEMMUNE, INCNIH RePORTER · 11183602 (opens the source filing in a new tab)

  2. R44

    SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites

    $1.0M

    Aug 17, 2023NIAIDEMMUNE, INCNIH RePORTER · 11141131 (opens the source filing in a new tab)

  3. R44

    Process development for manufacturing eCD4-Ig

    $1000k

    Jan 1, 2023NIAIDEMMUNE, INCNIH RePORTER · 11328776 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources